Bicyclic and Tricyclic Substituted 6-Methylidene Carbapenems as Broad Spectrum Beta-Lactamase Inhibitors
AssigneeWyeth
InventorsTarek Suhayl Mansour, Aranapakam Mudumbai Venkatesan
Life of this patent
Estimating the term…
Abstract
Provided is a β-lactamase antibiotic and a compound of formula I, a process of producing the compound, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.
Claims52
A compound of Formula I:
- wherein:
- one of A and B denotes hydrogen and the other an 8- to 14-membered fused bicyclic or tricyclic heteroaryl group optionally substituted with nitro, C6-14aryl, -heteroaryl, alkoxycarbonyl-, C1-6alkoxy, -alkoxyalkyl, alkyl-O—C2-4alkyl-O—, -cyano, -halogen, -hydroxy, —N—R6R7, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl-, alkoxyalkyl-, C1-6alkyl-S—, —SO2N—R6R7, —SO2NHR6, —CO2H, CONR6R7, C6-14aryl-O—, heteroaryl-O—, —S(═O)s-aryl where s is 0-2, -alkyl-O—-alkyl-NR6R7, -alkyl-aryl-O-alkylN—R6R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N—(C1-6alkyl), and —S(═O)s-heteroaryl where s is 0-2;
- R5 is H, C1-6alkyl, C5-6cycloalkyl, or CHR3OCOC1-6alkyl;
- R3 is hydrogen, C1-6alkyl, C3-7cycloalkyl, C6-14aryl, or 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, wherein aryl or heteroaryl can be optionally substituted with 1 or 2 of nitro, C6-14aryl, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, C1-6alkoxycarbonyl, C1-6alkoxy, -alkoxyalkyl, alkyl-O—C2-4alkyl-O—, -cyano, -halogen, -hydroxy, —NR6R7, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl-, alkoxyalkyl-, alkyl-S—, —SO2N—R6R7, aryl-O—, heteroaryl-O—, —S((═O)s-aryl where s is 0-2, -alkyl-O-alkyl-NR6R7, -alkyl-aryl-O-alkylN—R6R7, -alkyl-aryl-O—-alkylN—R6R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N-alkyl-, and —S(═O)s-heteroaryl where s is 0-2;
- and
- R6 and R7 are independently H, or a group selected from C1-6alkyl, C6-14aryl, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, alkylaryl, arylalkyl, heteroarylalkyl, C1-6alkylheteroaryl, said group being optionally substituted with nitro, C6-14aryl, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, C1-6alkoxycarbonyl-, C1-6alkoxy, -alkoxyalkyl, alkyl-O—C2-4alkyl-O-cyano, -halogen, -hydroxy, —NR6R7, —COOH, —COO-alkyl, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl, alkoxyalkyl-, C1-5alkyl-S—, —SO2NHR6, —CO2H, CONR6R7, C6-14aryl-O—, heteroaryl-O—, —S(═O)s-aryl, wherein s is 0-2, -alkyl-O-alkyl-NR6R7, -alkyl-aryl-O-alkyl-N—R6R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N-alkyl-, and —S(═O)s-heteroaryl, where s is 0-2;
- or R6 and R7 can together with the nitrogen to which they are attached form a 3 to 7 membered saturated ring system optionally having in addition to the nitrogen, one or two heteroatoms selected from N—R1, O, and S(═O)n, where n is 0-2;
- or a pharmaceutically acceptable salt thereof.
A method for treating a bacterial infection or disease comprising providing to a patient in need thereof an effective amount of cefepime or a pharmaceutically acceptable salt thereof and compound of formula I
- wherein:
- one of A and B denotes hydrogen and the other an 8- to 14-membered fused bicyclic or tricyclic heteroaryl group optionally substituted with nitro, C6-14aryl, -heteroaryl, C1-6alkoxycarbonyl-, C1-6alkoxy, -alkoxyalkyl, alkyl-O—C2-4alkyl-O—, -cyano, -halogen, -hydroxy, -N—R6R7, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl-, alkoxyalkyl-, alkyl-S—, —SO2N—R6R7, —SO2NHR6, —CO2H, CONR6R7, aryl-O—, heteroaryl-O—, —S(═O)s-aryl where s is 0-2, -alkyl-O-alkyl-NR6R7, -alkyl-aryl-O-alkylN—R6R7, C1-6alkyl, Cmalkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N—(C1-6alkyl), and —S(═O)s-heteroaryl where s is 0-2;
- R5 is H, C1-6alkyl, C5-6cycloalkyl, or CHR3OCOC1-6alkyl;
- R3 is hydrogen, C1-6alkyl, C3-7cycloalkyl, C6-14aryl, or 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, wherein aryl or heteroaryl can be optionally substituted with 1 or 2 of nitro, C6-14aryl, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, C1-6alkoxycarbonyl, C1-6alkoxy, -alkoxyalkyl, alkyl-O—C2-4alkyl-O—, -cyano, -halogen, -hydroxy, —NR6R7, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl-, alkoxyalkyl-, alkyl-S—, —SO2N—R6R7, aryl-O—, heteroaryl-O—, —S((═O)s-aryl where s is 0-2, -alkyl-O-alkyl-NR6R7, -alkyl-aryl-O-alkylN-R6R7, -alkyl-aryl-O-alkylN—R5R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N-alkyl-, and —S(═O)s-heteroaryl where s is 0-2;
- and
- R6 and R7 are independently H, or a group selected from C1-6alkyl, C6-14aryl, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, alkylaryl, arylalkyl, heteroarylalkyl, C1-6alkylheteroaryl, said group being optionally substituted with nitro, C6-14aryl, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from O, N, or S, a 5- to 10-membered mono or bicyclic saturated heterocyclyl having 1 to 3 heteroatoms selected from O, N, or S, C1-6alkoxycarbonyl-, C1-6alkoxy, -alkoxyalkyl, alkyl-O—C2-4alkyl-O-cyano, -halogen, -hydroxy, —NR6R7, —COON, —COO-alkyl, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl, alkoxyalkyl-, C1-6alkyl-S—, —SO2NHR6, —CO2H, CONR6R7, C6-14aryl-O—, heteroaryl-O—, —S(═O)s-aryl, wherein s is 0-2, -alkyl-NR6R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N-alkyl-, and —S(═O)5-heteroaryl, wherein S is 0-2, or R6 and R7 can together with the nitrogen to which they are attached form a 3 to 7 membered saturated ring system optionally having one or two heteroatoms selected from N—R1, O, and S(═O)n, where n is 0-2;
- or a pharmaceutically acceptable salt thereof.
A composition comprising a pharmaceutically acceptable carrier, cefepime or a pharmaceutically acceptable salt thereof, and a compound of formula I
- wherein:
- one of A and B denotes hydrogen and the other an 8- to 14-membered fused bicyclic or tricyclic heteroaryl group optionally substituted with nitro, -aryl, -heteroaryl, C1-6alkoxycarbonyl-, C1-6alkoxy, -alkoxyalkyl, alkyl-O-C2-4alkyl-O—, -cyano, -halogen, -hydroxy, -N—R6R7, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl-, alkoxyalkyl-, alkyl-S—, —SO2N—R6R7, —SO2NHR6, —CO2H, CONR6R7, aryl-O—, heteroaryl-O—, —S(═O)s-aryl where s is 0-2, -alkyl-O-alkyl-NR6R7, -alkyl-aryl-O-alkylN—R6R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N—(C1-6alkyl), and -S(═O)s-heteroaryl where s is 0-2;
- R5 is H, C1-6alkyl, C5-6cycloalkyl, or CHR3OCOC1-6alkyl;
- and
- R3 is hydrogen, C1-6alkyl, C3-7cycloalkyl, C6-14aryl, or heteroaryl, wherein aryl or heteroaryl can be optionally substituted with 1 or 2 of nitro, -aryl, -heteroaryl, C1-6alkoxycarbonyl, C1-6alkoxy, -alkoxyalkyl, alkyl-O—C2-4alkyl-O—, -cyano, -halogen, -hydroxy, —NR6R7, -trifluoromethyl, -trifluoromethoxy, arylalkyl, alkylaryl, R6R7N-alkyl-, HO—C1-6alkyl-, alkoxyalkyl-, alkyl-S—, —SO2N—R6R7, aryl-O—, heteroaryl-O—, —S((═O)s-aryl where s is 0-2, -alkyl-O-alkyl-NR6R7, -alkyl-aryl-O-alkylN—R6R7, -aryl-O-alkylN—R6R7, C1-6alkyl, C2-8alkenyl, C2-6alkynyl, C3-7cycloalkyl, alkoxy-alkyl-O—, R6R7N-alkyl-, and —S(═O)s-heteroaryl where s is 0-2;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.